Evidence map›Paper›PMID 36401817›Full record

ArticleHLA2023

Site-directed mutagenesis of HLA molecules reveals the functional epitope of a human HLA-A1/A36-specific monoclonal antibody.

Tina Meng, Suzanne Bezstarosti, Ujjwala Singh, Michelle Yap, Laura Scott, Naiiry Petrosyan, Fred Quiroz, Ned Van Eps, Eric Ka-Wai Hui, David Suh and 6 more

Abstract read
In one paragraph

Article in HLA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. The Progress and Challenges of Implementing HLA Molecular Matching in Clinical Practice.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tina MengDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0002-3768-8756
Suzanne BezstarostiDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-0315-115X
Ujjwala SinghDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0002-4259-9678
Michelle YapDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0002-0123-0030
Laura ScottDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0002-9968-0039
Naiiry PetrosyanDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0002-3836-9490
Fred QuirozDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0001-8070-7206
Ned Van EpsDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0001-9178-1436
Eric Ka-Wai HuiDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0001-7981-3925
David SuhDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0002-6707-6187
Quansheng ZhuDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0001-8030-014X
Rui PeiDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0002-7742-5627
Cynthia S M KramerDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1350-2336
Frans H J ClaasDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-4157-6201
David LoweDepartment of Research and Development, One Lambda, Inc. (A Part of Thermo Fisher Scientific Inc.), West Hills, California, USA.ORCID 0000-0001-9810-2344
Sebastiaan HeidtDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-6700-188X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eplet 44KM is currently listed in the HLA Epitope Registry but does not adhere to the eplet definition of an amino acid configuration within a 3.5 Å radius. Eplet 44KM has been previously redefined to the antibody-verified reactivity pattern 44K/150V/158V, based on reactivity analysis of monoclonal antibody VDK1D12. Since the three residues are always simultaneously present on common HLA alleles, methods to define which residue is crucial for antibody-induction and binding are limited. In this proof-of-concept study, we performed site-directed mutagenesis to narrow down the antibody-verified reactivity pattern 44K/150V/158V to a single amino acid and defined 44K as the eplet or functional epitope of mAb VDK1D12.

Indexed as

Antibodies, MonoclonalHLA-A1 AntigenAllelesAmino AcidsAntibody SpecificityEpitopesHistocompatibility TestingHLA-A AntigensHumansMutagenesis, Site-DirectedAmino AcidsAntibodies, MonoclonalEpitopesHLA-A1 AntigenHLA-A Antigensantibody verificationantigenicityepletimmunogenicitymonoclonal antibodyreactivity patternsite-directed mutagenesis

Identifiers

PMID36401817
PMCPMC10099858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.